ABCL (AbCellera Biologics) Insider Ownership: 1.69 % (As of Jul. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ABCL AbCellera Biologics Inc ABCL
60 GF Score
Price $5.80
GF Value $5.26
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is AbCellera Biologics Insider Ownership?

AbCellera Biologics ABCL -10.29% 60 Insider Ownership is 1.69 % as of Jul. 20, 2026. GuruFocus rates ABCL with a GF Score™ of 60/100 and a GF Value™ of $5.26 (Fairly Valued). The stock has 3 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, AbCellera Biologics's insider ownership is 1.69%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, AbCellera Biologics's Institutional Ownership is 40.70%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, AbCellera Biologics's Float Percentage Of Total Shares Outstanding is 77.16%.

AbCellera Biologics Insider Ownership Historical Data

* Premium members only.

The historical data trend for AbCellera Biologics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AbCellera Biologics Insider Ownership Chart

AbCellera Biologics Historical Data

The historical data trend for AbCellera Biologics can be seen below:

2025-06-30 2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30
Insider Ownership 1.49 1.49 1.48 1.48 1.48 1.50 1.62 1.62 1.61 1.69
ABCL
60GF Score
AbCellera Biologics Inc ABCL
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AbCellera Biologics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 1.69 % mean?
AbCellera Biologics (ABCL) has a Insider Ownership of 1.69 % as of Jul. 20, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on AbCellera Biologics and its competitors.
Is AbCellera Biologics' Insider Ownership too high?
AbCellera Biologics' current Insider Ownership is 1.69 %. Overall, AbCellera Biologics has a GF Score™ of 60/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does AbCellera Biologics' Insider Ownership compare to AGIO and KOD?
AbCellera Biologics' Insider Ownership of 1.69 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on AbCellera Biologics and its competitors. AbCellera Biologics's current Insider Ownership is 1.69 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbCellera Biologics stock overvalued right now?
Based on GuruFocus' analysis, AbCellera Biologics (ABCL) is currently considered Fairly Valued. The stock's GF Value™ is $5.26, compared to a current price of $5.80 — trading 10.3% above its estimated fair value. The current Insider Ownership is 1.69 %. AbCellera Biologics' overall GF Score™ is 60/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For AbCellera Biologics (ABCL), the current Insider Ownership is 1.69 % as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AbCellera Biologics (ABCL) Overvalued in 2026?

Based on GuruFocus' analysis, AbCellera Biologics stock appears to be overvalued. The current stock price of $5.80 is trading 10.3% above its estimated GF Value™ of $5.26. GuruFocus considers AbCellera Biologics to be Fairly Valued.

Key valuation signals for ABCL:

  • Insider Ownership: 1.69 %
  • GF Value™: $5.26 vs. price of $5.80 (10.3% above fair value)
  • GF Score™: 60/100 with 3 warning signs

No single metric tells the full story. See the ABCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AbCellera Biologics Business Description

Other Exchanges 8QQ:Germany
Address 150 W 4th Avenue, Vancouver, BC, CAN, V5Y 1G6
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
60GF Score

Get the complete analysis for ABCL

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.80
Price
$5.26
GF Value